EA202090270A1 - Новые замещенные производные ксантина - Google Patents

Новые замещенные производные ксантина

Info

Publication number
EA202090270A1
EA202090270A1 EA202090270A EA202090270A EA202090270A1 EA 202090270 A1 EA202090270 A1 EA 202090270A1 EA 202090270 A EA202090270 A EA 202090270A EA 202090270 A EA202090270 A EA 202090270A EA 202090270 A1 EA202090270 A1 EA 202090270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
xanthine derivatives
substituted xanthine
new substituted
derivatives
new
Prior art date
Application number
EA202090270A
Other languages
English (en)
Other versions
EA039526B1 (ru
Inventor
Кай Герлах
Кристиан Айкмайер
Ахим Зауэр
Штефан Юст
Бертран Л. Шенар
Original Assignee
Берингер Ингельхайм Интернациональ Гмбх
ХАЙДРА БАЙОСАЙЕНСИЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берингер Ингельхайм Интернациональ Гмбх, ХАЙДРА БАЙОСАЙЕНСИЗ, ЭлЭлСи filed Critical Берингер Ингельхайм Интернациональ Гмбх
Publication of EA202090270A1 publication Critical patent/EA202090270A1/ru
Publication of EA039526B1 publication Critical patent/EA039526B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к замещенным производным ксантина, фармацевтическим композициям, содержащим их, и их применению в терапии, особенно при лечении состояний, связанных с TRPC5-содержащими ионными каналами.
EA202090270A 2017-07-11 2018-07-06 Новые замещенные производные ксантина EA039526B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (2)

Publication Number Publication Date
EA202090270A1 true EA202090270A1 (ru) 2020-04-24
EA039526B1 EA039526B1 (ru) 2022-02-07

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090270A EA039526B1 (ru) 2017-07-11 2018-07-06 Новые замещенные производные ксантина

Country Status (30)

Country Link
US (1) US10329292B2 (ru)
EP (1) EP3652176B1 (ru)
JP (1) JP7114702B2 (ru)
KR (1) KR20200030048A (ru)
CN (1) CN110997675B (ru)
AR (1) AR112448A1 (ru)
AU (1) AU2018299824B2 (ru)
BR (1) BR112019025611A2 (ru)
CA (1) CA3066922A1 (ru)
CL (1) CL2020000056A1 (ru)
CO (1) CO2019015102A2 (ru)
CY (1) CY1125014T1 (ru)
DK (1) DK3652176T3 (ru)
EA (1) EA039526B1 (ru)
ES (1) ES2903268T3 (ru)
HR (1) HRP20220029T1 (ru)
HU (1) HUE057600T2 (ru)
IL (1) IL271799B (ru)
LT (1) LT3652176T (ru)
MX (1) MX2020000402A (ru)
PH (1) PH12020500079A1 (ru)
PL (1) PL3652176T3 (ru)
PT (1) PT3652176T (ru)
RS (1) RS62826B1 (ru)
SA (1) SA519410851B1 (ru)
SG (1) SG11201912168TA (ru)
SI (1) SI3652176T1 (ru)
TW (1) TWI801398B (ru)
UA (1) UA124793C2 (ru)
WO (1) WO2019011802A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3894409B1 (en) * 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
ES2964630T3 (es) * 2018-12-12 2024-04-08 Boehringer Ingelheim Int Derivados de xantina sustituidos
KR20220079907A (ko) * 2019-10-04 2022-06-14 골드핀치 바이오 인코포레이티드 국소분절사구체경화증 및 당뇨병성 신장 질환의 바이오마커 기반 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP2044029B1 (en) * 2006-07-14 2011-01-26 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
RS56066B2 (sr) * 2013-03-15 2018-09-28 Hydra Biosciences Inc Supstituisani ksantini i postupci za njihovu upotrebu
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Also Published As

Publication number Publication date
ES2903268T3 (es) 2022-03-31
UA124793C2 (uk) 2021-11-17
CA3066922A1 (en) 2019-01-17
TWI801398B (zh) 2023-05-11
SG11201912168TA (en) 2020-01-30
CY1125014T1 (el) 2023-03-24
CN110997675B (zh) 2022-06-07
AU2018299824B2 (en) 2022-06-16
EP3652176B1 (en) 2021-12-15
KR20200030048A (ko) 2020-03-19
TW201908318A (zh) 2019-03-01
AR112448A1 (es) 2019-10-30
IL271799B (en) 2022-08-01
PT3652176T (pt) 2022-01-13
CN110997675A (zh) 2020-04-10
EP3652176A1 (en) 2020-05-20
JP7114702B2 (ja) 2022-08-08
JP2020526591A (ja) 2020-08-31
PL3652176T3 (pl) 2022-04-04
US10329292B2 (en) 2019-06-25
HRP20220029T1 (hr) 2022-04-15
IL271799A (en) 2020-02-27
CL2020000056A1 (es) 2020-06-12
SA519410851B1 (ar) 2023-02-26
PH12020500079A1 (en) 2020-10-05
SI3652176T1 (sl) 2022-04-29
HUE057600T2 (hu) 2022-05-28
AU2018299824A1 (en) 2019-12-19
EA039526B1 (ru) 2022-02-07
WO2019011802A1 (en) 2019-01-17
LT3652176T (lt) 2022-02-25
DK3652176T3 (da) 2022-01-17
RS62826B1 (sr) 2022-02-28
MX2020000402A (es) 2020-08-17
CO2019015102A2 (es) 2020-05-15
BR112019025611A2 (pt) 2020-06-16
US20190016722A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
MY187540A (en) Compounds active towards bromodomains
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA202090683A3 (ru) Способы и композиции для лечения рака
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2017009608A (es) Compuestos anticancerigenos.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
CY1122708T1 (el) Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου